Lumos Pharma (NASDAQ: LUMO), a biopharmaceutical company advancing an oral therapeutic candidate for pediatric growth hormone deficiency (“PGHD”) through phase 2 clinical trials, has received a notice of allowance for a submitted patent. The notice was received from the U.S. Patent and Trade Office (“USPTO”) earlier this month; the notice covers claims the company made for its patent titled “Compactable Oral Formulations of Ibutamoren.” According to the announcement, the patent includes improved formulations of LUM-201 that the company plans to use in its phase 3 trial and eventually commercialize. LUM-201 (ibutamoren) is an orally administered small molecule that promotes the secretion (secretagogue) of growth hormone from the pituitary gland. The patent grant provides intellectual property protection through November 2042. “We are excited to announce that LUM-201 has been granted a novel formulation patent by the USPTO, which is enabled by unique properties of this molecule achieved through our improved manufacturing processes,” said Lumos Pharma chair and CEO Rick Hawkins in the press release. “Importantly, this new patent extends our exclusivity of LUM-201 through 2042, surpassing our current method of use patent expiration in 2036. This novel formulation of LUM-201 permits a capsule with mini-tablets, which should reduce dose variance and enable easier administration for younger children. We intend to employ this formulation in our upcoming phase 3 trial evaluating oral LUM-201 in moderate pediatric growth hormone deficiency expected to start in Q4 2024, and eventually in the commercial setting following potential regulatory approval of LUM-201.”
To view the full press release, visit https://ibn.fm/GHT1i
About Lumos Pharma Inc.
Lumos Pharma is a clinical-stage biopharmaceutical company focused on the development and commercialization of therapeutics for rare diseases. The company was founded and is led by a management team with longstanding experience in rare disease drug development. Lumos Pharma’s lead therapeutic candidate, LUM-201, is a novel, oral growth hormone (“GH”) secretagogue, seeking to transform the ~$4.7 billion global GH market from injectable to oral therapy. LUM-201 is currently being evaluated in multiple phase 2 clinical studies in PGHD and has received orphan drug designation in both the United States and the European Union. For more information, please visit www.Lumos-Pharma.com
About InvestorWire
InvestorWire (“IW”) is a specialized communications platform with a focus on advanced wire-grade press release syndication for private and public companies and the investment community. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, IW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, IW brings its clients unparalleled recognition and brand awareness. IW is where breaking news, insightful content and actionable information converge.
For more information, please visit https://www.InvestorWire.com
Please see full terms of use and disclaimers on the InvestorWire website applicable to all content provided by IW, wherever published or re-published: https://www.InvestorWire.com/Disclaimer
InvestorWire
Los Angeles, CA
www.InvestorWire.com
310.299.1717 Office
[email protected]
InvestorWire is powered by IBN